Recent research shows that prostate cancer screening can significantly reduce mortality rates from the disease by approximately 50%.
Findings presented at the 2025 European Association of Urology Congress examined the mortality risk from prostate cancer among high-risk men who haven’t undergone prostate cancer screening using prostate-specific antigen (PSA) levels.
Prostate cancer is the most commonly diagnosed cancer among men across 112 countries globally. Diagnoses are on the rise, with prevalence expected to double by 2040.
Screening for prostate cancer is possible through a blood test that measures PSA levels. This allows early detection and treatment, boosting cure rates and reducing costs associated with advanced forms of prostate cancer care.
Long-term studies indicate PSA screening can reduce prostate cancer mortality risk by about 20%.
Researchers analyzed 20 years of prostate cancer screening data to examine how forgoing PSA screening impacts the risk of death from the disease.
The study was the largest of its kind in the world for prostate cancer screening and included more than 160,000 men in 7 European countries.
Study results showed that among high-risk men, 12,400 did not undergo screening. These individuals faced a 45% higher risk of dying from prostate cancer compared to those who received regular screenings.
Based on these findings, researchers concluded that prostate cancer screening dramatically reduces mortality risk from the disease.
Most Commented